Stockscreener 앱 받기
7.64
0.00%
0.00
시간 외 거래:
7.64
전일 마감가:
$7.64
열려 있는:
$7.52
하루 거래량:
518.77K
Relative Volume:
1.07
시가총액:
$5.20B
수익:
$8.62B
순이익/손실:
$573.80M
주가수익비율:
10.81
EPS:
0.707
순현금흐름:
$680.05M
1주 성능:
+3.66%
1개월 성능:
+4.51%
6개월 성능:
-12.69%
1년 성능:
-20.83%
1일 변동 폭
$7.50
$7.67
1주일 범위
$7.22
$7.75
52주 변동 폭
$6.96
$9.90
그리폴스 Stock (GRFS) Company Profile
Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.64 | 5.20B | 8.62B | 573.80M | 680.05M | 0.707 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
그리폴스 Stock (GRFS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 재개 | Morgan Stanley | Overweight |
| 2024-03-12 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-04-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2023-01-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-04-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-10-19 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2021-10-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-06-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 개시 | Deutsche Bank | Hold |
| 2021-03-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2020-10-01 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-06-09 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-06-09 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-03-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-06-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-02-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2018-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-06-01 | 개시 | Barclays | Overweight |
| 2017-10-31 | 개시 | Citigroup | Buy |
| 2017-06-30 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-04-06 | 개시 | BofA/Merrill | Buy |
| 2017-01-03 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-02-09 | 업그레이드 | Berenberg | Hold → Buy |
| 2016-01-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2015-11-20 | 다운그레이드 | Berenberg | Buy → Hold |
| 2015-04-28 | 다운그레이드 | Berenberg | Buy → Hold |
모두보기
그리폴스 주식(GRFS)의 최신 뉴스
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance Australia
Grifols, S.A. (GRF.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance Singapore
Grifols, S.A. - Reuters
Grifols stock trades below recent highs as valuation focus grows - ad-hoc-news.de
Grifols SA Lobbying Profile, 2024 - OpenSecrets
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Grifols stock edges lower as investors weigh recent earnings and valuation - ad-hoc-news.de
Grifols SA Lobbyists, 2024 - opensecrets.org
Grifols SA Lobbying Profile, 2020 - OpenSecrets
Operating margin % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Return on invested capital % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Return on equity % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Price to earnings ratio of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
G0F Forecast — Price Target — Prediction for 2027 - TradingView
G0F Stock Price and Chart — HAM:G0F - TradingView
Grifols stock holds below $8 as half-year 2026 earnings highlight margin progress - ad-hoc-news.de
Grifols stock holds in single digits as Q2 2026 earnings miss consensus by a small margin - Ad-hoc-news.de
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
Grifols Up Over 6%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk - Moomoo
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - tradingview.com
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency - barchart.com
Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48Insider Buying Alerts - vinanet.vn
Grifols, S.A. Class A Revenue Breakdown – BME:GRF - TradingView
Grifols (GRFS) reshapes board, Audit and Strategy Committees - Stock Titan
Grifols shares jump after Q2 results exceed expectations - Investing.com
Grifols, S.A. Sponsored ADR Class A Revenue Breakdown – MUN:G0F - TradingView
Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Grifols (GRFS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ... - finance.yahoo.com
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols SA expected to post earnings of 24 cents a shareEarnings Preview - TradingView
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Grifols, S.A. Class A – BME:GRF - TradingView
GRFSGrifols SA ADR Options - Finviz
GRFSGrifols SA ADR Volatility & Greeks - Finviz
GRFSGrifols SA ADR Volatility & Greeks - Finviz
GRFSGrifols SA ADR Latest SEC Filings - Finviz
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
GRFSGrifols SA ADR Options - Finviz
GRFSGrifols SA ADR Forecast, Target Price - Finviz
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de
그리폴스 (GRFS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
1.86%
자본화:
|
볼륨(24시간):